- Home
- QCRH vs CERT Comparison
QCRH vs CERT Comparison
Compare QCRH & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QCRH | CERT |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QCRH | CERT |
|---|---|---|
| Price | $102.87 | $10.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $110.50 | $9.17 |
| AVG Volume (30 Days) | 96.3K | ★ 2.6M |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | 11.62 | ★ 87.50 |
| EPS | ★ 4.18 | N/A |
| Revenue | $165,999,610.00 | ★ $418,838,000.00 |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | $5.31 | $2.54 |
| P/E Ratio | $23.81 | ★ N/A |
| Revenue Growth | ★ 20.72 | 8.75 |
| 52 Week Low | $71.69 | $4.45 |
| 52 Week High | $108.11 | $12.94 |
Technical Indicators
Market Signals| Indicator | QCRH | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 61.78 |
| Support Level | $102.52 | $8.82 |
| Resistance Level | $103.62 | $10.20 |
| Average True Range (ATR) | 2.40 | 0.54 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 90.95 | 83.53 |
Price Performance
Historical ComparisonAbout QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.